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Amadori glucose adducts modulate mesangial cell growth and collagen
gene expression. Diabetic serum contains increased concentrations of
glycated proteins, which are preferentially transported into the renal
glomerulus. We investigated effects of Amadori glucose adducts in
serum proteins, the predominant form in which circulating glycated
proteins exist in vivo, on glomerular mesangial cells, where the lesion of
diabetic nephropathy originates. [3H]-thymidine incorporation by mu-
rine mesangial cells was significantly inhibited when cells were grown in
the presence of serum glycated by incubation for four days with 28 mM
glucose or when cells were cultured in microtiter plates that had been
precoated with glycated serum. This effect was prevented by a mono-
clonal antibody immunoreactive with Amadori adducts in glycated
albumin, and unreactive with other glycated serum proteins or with
advanced glycation end (AGE) products. Glycated serum stimulated
Type IV collagen gene expression and increased Type IV collagen
secretion, an effect also prevented by monoclonal antibodies reactive
with Amadori adducts in glycated albumin. The glycation-induced
changes in proliferation, collagen synthesis and collagen gene expres-
sion were observed in media containing normal glucose concentration
and were exaggerated in media containing high glucose concentration.
The data indicate that Amadori products of glycated serum proteins
induce mesangial cell abnormalities that are highly relevant to the
pathogenesis of diabetic nephropathy, and that these effects are accen-
tuated when glycated serum proteins are presented in a hyperglycemic
milieu. The data also suggest that mesangial cells specifically recognize
Amadori adducts in glycated albumin.
The glomerular mesangial cell is intimately involved in the
development of diabetic nephropathy, which is characterized
by glomerular hypertrophy, mesangial matrix accumulation in
association with decreased cellularity, and a thickened glomer-
ular basement membrane [1—4]. Mesangial cells synthesize
Type IV collagen, the predominant constituent of the expanded
mesangial matrix that is observed in the diabetic glomerulus,
and we and others have used mesangial cell proliferative and
biosynthetic responses to media manipulations to investigate
potential nephropathic factors [5—i 1]. High glucose concentra-
tion causes delayed growth inhibition in association with bio-
activation of transforming growth factor-beta, and induces
increased mesangial cell Type IV collagen production and gene
expression [6, 9—11]. These findings are interpreted to support a
Received for publication June 9, 1993
and in revised form September 25, 1993
Accepted for publication September 26, 1993
© 1994 by the International Society of Nephrology
causal role of hyperglycemia in the pathogenesis of diabetic
nephropathy. However, responses to high glucose in serum-
free media may not satisfactorily address the diabetic milieu in
vivo, where the mesangium is bathed in serum containing
increased concentrations of nonenzymatically glycated serum
proteins.
Nonenzymatic glycation (NEG) refers to the condensation
between glucose and reactive protein amino groups that results
in the formation of stable adducts in Amadori configuration
[12—14]. Although subsequent rearrangement reactions may
occur, the Amadori adduct is the predominant form in which
circulating glycated proteins exist in vivo, and its concentration
is significantly increased in diabetes with attendant hyperglyce-
mia [2, 13, 15—19]. For example, a recent study describing
immunochemical analysis of advanced glycation end (AGE)
products in normal and diabetic human serum reports concen-
trations of 10 to 25 UIml, equivalent to <0.01% of serum
proteins, whereas Amadori products typically constitute 2 to
10% [20]. We became interested in the potential role of NEG of
serum proteins in diabetic nephropathy in light of the above, as
well as several studies demonstrating adverse effects of gly-
cated serum proteins on glomerular physiology and biochemis-
try. Glycated serum proteins are preferentially transported
across the glomerular filtration barrier, and glomerular mesan-
gial and epithelial cells exhibit enhanced uptake of glycated
albumin, which is accompanied by an increase in cell hydrogen
peroxide production [21—24]. A most striking finding is the
induction of glomerular hyperfiltration, an early functional
abnormality implicated in the development of diabetic nephrop-
athy, in normal rats transfused with glycated serum proteins
containing Amadori products of the glycation reaction in con-
centrations similar to those found in streptozotocin-diabetic
rats [25].
In approaching study of the influence of serum protein
glycation on mesangial cell biology, we considered it important
that the glycated proteins be represented as the early (Amadori)
glycation products, and therefore adhered to conditions for
glycation known to yield Amadori and not AGE modifications
[25, 26]. We also examined effects in both normal and elevated
media glucose concentration. In this manner, we hoped to
delineate glycation-induced from glucose-induced responses,
although we anticipated that effects might be additive. Addi-
tionally, we used a monoclonal antibody that has been shown to
immunoreact with Amadori glucose adducts in albumin and to
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be unreactive with AGE-modified human albumin to identify
the contribution of this principle serum protein to glycation-
induced abnormalities [27]. We report that exposure of mesan-
gial cells in culture to glycated serum proteins inhibits prolifer-
ation and stimulates Type IV collagen gene transcription and
production, and that high glucose concentration in the culture
media exaggerates these effects. The glycated serum-induced
decrease in cell proliferation and increase in collagen produc-
tion are prevented by monoclonal antibodies reactive with
glycated epitopes in albumin, implicating Amadori products of
nonenzymatically glycated albumin in the genesis of mesangial
abnormalities that are highly relevant to the pathogenesis of
diabetic nephropathy.
Methods
Cell culture
Murine mesangial cells in culture were derived from glomer-
uli isolated from SJL/J mice with a graded sieving technique and
plated to explant [28, 29}. Mesangial cells were selected and
subcultured according to previously described criteria [281,
including morphology, their ability to grow in medium contain-
ing D-valine instead of L-valine, and the presence of cytoplas-
mic filaments (desmin and vimentin), angiotensin II binding
capacity, and contractile response to angiotensin II. Experi-
ments examining the influence of glycated serum on mesangial
cell proliferation used cells stabilized in long-term culture by
virus transformation with SV-40 and carried in DMEM contain-
ing 5.5 m glucose and 10% fetal calf serum (FCS). The
suitability of transformed mesangial cells, and their parallelism
with non-transformed cells with respect to growth and response
to media manipulations, have been documented [11]. Experi-
ments examining the effects of glycated proteins on Type IV
collagen production and gene expression used phenotypically
stable non-transformed cells grown to 10 to 16 passages in
RPMI containing 10 m glucose and 10% FCS. To initiate
experiments under varying culture conditions, mesangial cells
were plated into 75 cm2 plastic flasks or 24- to 96-well plastic
microtiter plates, grown to confluence for two days, rested for
one day in serum-free medium containing 5.5 m glucose, and
then grown for 48 to 96 hours in fresh DMEM containing 5.5
m or 25 m glucose without or with the addition of supple-
ments described below.
Culture conditions
Media supplements consisted of FCS or normal or glycated
human serum, and A717 monoclonal antibody or IgG not
reactive with glycated albumin. Where indicated for studies on
collagen secretion, media also were supplemented with 50
g/ml each of ascorbic acid and J3-aminopropionitrile. For
glycation, normal human serum was sterile filtered, incubated
for four to five days at 25°C with 28 m glucose in phosphate
buffered saline (PBS), dialyzed against PBS, and again sterile
filtered. Unincubated serum also was dialyzed against PBS to
control for the effect of dialysis, and sterile ifitered. Cell
cultures were supplemented to 3 to 10% with FCS, unincubated
or glucose-incubated serum, without or with affinity-purified
monoclonal antibody A717 or other IgG in PBS (5 to 20 tg!ml
final concentration in cell cultures). Production and character-
ization of the A717 monoclonal antibody have been described
[271. This antibody was raised in mice immunized with glycated
albumin purified by affinity chromatography on phenylboronate
agarose (PBA) of albumin isolated from human plasma. The
immunogen therefore contained Amadori adducts, which bind
to PBA, and not AGE products, which do not. The specificity of
the A717 monoclonal antibody used in these experiments for
glycated epitopes residing in albumin was confirmed with
immunoblotting and enzyme-linked immunosorbent assay
(ELISA). Antigens tested included nonglycated albumin and
nonenzymatically glycated hemoglobin, apolipoprotein B (apo
B), fibronectin, and fibronectin auto-digest peptides from 30,000
to 120,000 molecular weight. The glycated species were purified
by PBA affinity chromatography from the corresponding pro-
teins isolated from erythrocyte lysates and human plasma,
respectively.
Antibody spec(ilcity
For immunoblotting, samples were electrophoresed on 12%
polyacrylamide gels, and the proteins were transferred electro-
phoretically to nitrocellulose filters. The transfers were incu-
bated with A717 antibody and developed with an alkaline
phosphatase (AP) immunoblot system. ELISA was performed
by immobilizing antigen onto microtiter wells in carbonate!
bicarbonate coupling buffer, pH 9.5 for four hours at room
temperature. Unbound antigen was aspirated and the wells
were blocked with 4% milk in glycine coupling buffer, pH 8.5
overnight at 4°C. After washing with 0.15 M NaCl containing
0.01 M triethanolamine, 0.05% Tween 20 and 0.02% Proclin, pH
6.8, 1 g of monoclonal antibody A7l7 in 0.1 m tetrasodium
EDTA, 0.17 mri disodium EDTA, 0.15 M NaCI, pH 6.5 was
added and allowed to react for two hours at room temperature.
After washing with TEAJNaCIJTween wash buffer, horseradish
peroxidase (HRP)-conjugated goat anti-mouse IgG (BioRad,
Richmond, California, USA; 1:3000 dilution in 0.15 M saline, 10
mM Tris-acetate, 0.1% milk) was added and incubated for one
hour at room temperature. Color was developed with TMBlue
substrate and, after stopping with 2 M sulfuric acid, absor-
bances were read at 450 nm.
Cell growth
[3H]-thymidine incorporation assays were performed in 96-
well microtiter plates in 200 pi total volume. At the end of a
48-hour incubation period with unsupplemented or supple-
mented media, cells were pulsed for eight hours with PH]-
thymidine (1 CiIwell; 5 to 7 Ci!mmol; Amersham, Arlington
Heights, Illinois, USA). Cells were collected on glass microfi-
ber filters (934-AH, Whatman, Clifton, New Jersey, USA) using
a cell harvester, and radioactivity was assayed after placing the
filters in liquid scintillation fluid and counting in a liquid
scintillation counter [11, 301. In parallel studies, mesangial cells
were cultured in 24 well plates under similar conditions, the
media were then saved for Type IV collagen assay (see below),
and harvested cells were counted with an automated cell
counter (Coulter Electronics).
RNA isolation and Northern blot analysis
For each experiment, 2 x 106 mesangial cells plated into
plastic flasks and cultured as described were used for RNA
isolation. Exposure under the different experimental culture
conditions was conducted for 72 to 96 hours in order to
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maximize cell density and RNA recovery. The cells were lysed
and denatured by adding to the flasks 4 M guanidinium thiocy-
anate, 25 m sodium citrate (pH 7.0), 0.5% sarcosyl and 0.1 M
2-mercaptoethanol. Total RNA was then extracted by treat-
ment with phenol-chloroform according to Chomcyzynski and
Sacchi [31]. Ten to 20 jsg of total RNA, assayed by UV
spectrophotometry, was electrophoresed through a 1% agarose
gel with 2.2 M formaldehyde. RNA transfer to positively
charged nylon membrane was performed by electroblotting
followed by short-wave UV cross linking and prehybridization
as described [32]. Hybridization was conducted for 20 hours at
42°C using excised cDNA inserts labeled with [32P]-dCTP as
probes [33]. The cDNA probes used were a 0.65 kb fragment
encoding the mouse alpha 1 chain of the Type IV collagen gene
and a 1.3 kb Pst I fragment encoding the rat glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) gene. After hybridization,
the membranes were washed and exposed to x-ray film as
described [32]. The filters were first probed with the Type IV
collagen cDNA. To account for variations in RNA loading and
transfer, the filters subsequently were stripped for one to two
hours at 65°C with a solution containing 5 mM Tris, 0.2 mM
EDTA (pH 8.0) and 5% sodium pyrophosphate in order to
remove the signal. The filters were then rehybridized with the
GAPDH cDNA probe.
Type IV collagen secretion
Media were removed at the end of the incubation period and
immediately stored at —70°C until use. Type IV collagen was
measured by competitive enzyme-linked immunoassay
(ELISA) using Type IV collagen from Engelbreth-Holm Swarm
tumor as standard, rabbit anti-mouse Type IV collagen as
primary antibody (both from Collaborative Research), and
HRP-conjugated goat anti-rabbit immunoglobulin as detector
(BioRad). Type IV collagen was immobilized onto microtiter
plate wells in 0.05 M HCI overnight at 4°C and, after washing,
wells were blocked for one hour at room temperature with
PBS/10% FCS. Incubation with standard (5 to 500 ng/well
diluted in culture media containing 10% FCS) or sample, after
addition of primary antibody (1:8000 dilution), was for one hour
at room temperature. After washing, wells were incubated with
HRP-conjugated anti-rabbit IgG (1:3000 dilution) for 30 min-
utes, followed by washing, addition of TMB1ue substrate (mi-
crowell peroxidase system), stopping with 2 M H2S04, and
reading absorbances at 450 nm. The assay was sensitive to 5
nglwell.
Protein synthesis
Total protein synthesis in cultured mesangial cells was as-
sessed by tritiated leucine incorporation, and expressed as
cpmJlO3 cells as previously described [30].
Results
Previous studies examining the effect of glycated proteins on
mesangial cell growth and matrix biosynthesis have used pro-
teins extensively modified by AGE products and crosslinks [7,
34]. These studies found that [3H]-thymidine incorporation was
inhibited when cells were plated onto matrix containing fluo-
rescent, cross-linked glycation products obtained after long-
term exposure to high concentrations of glycoaldehyde or
glucose-6-phosphate (G-6-P). To optimize conditions in this
Table 1. Fluorescence of normal and glycated human serum
Unincubated
serum
Glycated
serum
Fluorescence 16 19
arbitrary units/mi
Absorbance 280 nm/mi 1.29 1.29
Protein mg/mi 36.0 34.0
Albumin mg/mi 27.7 24.9
Fluorescence was determined in a spectrofluorometer using an exci-
tation wavelength of 360 nm, an emission wavelength of 415 nm, and a
slit width of 2 mm both for excitation and emission. For comparative
purposes, arbitrary fluorescence units/mi in solubilized tissue protein
from diabetic rats ranged from 300 to 600, and fluorescence normalized
per mg of protein ranged from 150 to 300.
study for the generation of Amadori adducts and minimize
AGE-product formation, incubation with glucose was kept to
four to five days in the presence of 28 m glucose, conditions
which generate little if any AGE products [25, 26, 35]. For
example, the pyrraline AGE compound reported by Miyata and
Monnier does not form in albumin incubated with 50 mt
glucose until 20 days of incubation [35]. AGE-bovine serum
albumin is typically prepared by incubating the protein for four
to six weeks with 0.25 to 1.0 M glucose or G-6-P [8, 20, 34]. We
sought evidence of AGE-product formation by examining the
unincubated and glucose-incubated sera used in this study for
fluorescence and by SDS-gel electrophoresis. The two prepara-
tions yielded minimal fluorescence at excitation and emission
wavelengths of 360 nm and 415 nm, respectively (Table 1) and,
compared with unincubated sera, no new high molecular weight
cross-linked bands were discerned in the glycated preparations
subjected to SDS-polyacrylamide gel electrophoresis on 7.5%
or 12% gels under reducing or non-reducing conditions (not
shown). These findings support the interpretation that there is
not significant AGE product formation after four days of
incubation in 28 m glucose.
We also showed that the glucose-incubated sera reacted
strongly with the A717 monoclonal antibodies, which selec-
tively recognize Amadori adducts in glycated albumin and do
not react with nonglycated albumin, AGE-albumin, or other
proteins, whether glycated or not. Glucose-incubated serum,
which contains many glycated proteins, exhibited only one
immunoreactive band showing co-identity with (glycated) albu-
min when immunoblotted with the A7l7 antibody (Fig. 1).
Glycated hemoglobin (Fig. 1) and other glycated proteins con-
taining Amadori adducts (apo B, fibronectin) did not react with
A717 on Western blot. In ELISA, A717 exhibited a dose
response reactivity with purified glycated albumin, in both
unreduced and reduced constructs (Fig. 2). Since borohydride
converts the ketoamine to glucitol-lysine, these findings indi-
cated that the ketoamine structure is not exclusively necessary
for recognition, which we have previously noted [27]. Preser-
vation of reactivity after borohydnde reduction is consistent
with recognition of a linear form of the Amadori adduct, which
is in equilibrium with the furanose configuration, with equilib-
rium shifted to the linear form upon borohydride reduction.
None of the other tested purified glycated proteins reacted in
ELISA with the A717 monoclonal antibody, consistent with the
interpretation that the Amadori adduct epitope is encompassed
in an albumin specific domain.
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Fig. 1. Specificity of A717 monoclonal antibody for glycated epitopes
residing in albumin. Electrophoresed samples were glycated albumin
purified from normal plasma by sequential chromatography on Affi-gel
Blue and PBA (lane 4), serum incubated for 4 days with 28 m glucose
(lanes 5 and 6), and albumin glycated in vitro for 7 days with 28 mM
glucose (lane 7). Deglycated human albumin (pass-through from PBA)
shown in lane 3. Glycated hemoglobin purified from human red cell
lysates by sequential ion exchange and affinity (PBA) chromatography
shown in lane 2. Molecular weight standard is shown on left (lane I)
where A = 106K (phosphorylase B); B 80K (bovine serum albumin);C = 49.5K (ovalbumin); D = 32.5K (carbonic anhydrase); E = 27.5K
(soybean trypsin inhibitor).
1.5
Glycated albumin, tg
Fig. 2. Reactivity of unreduced (I) and borohydride-reduced (0)
glycated albumin in ELISA with ,nonoclonal antibody A 717. Each point
represents the mean of 6 observations; standard errors were less than
0.05 absorbance units for each point.
[3H]-thymidine incorporation by murine mesangial cells in
culture was stimulated in a dose response manner by the
addition of normal human serum to media containing 5.5 ms
glucose (Fig. 3). Mesangial cells proliferated more readily after
short-term (48 hours) incubation in serum-free culture media
containing 25 than 5.5 m glucose (Fig. 3). We have previously
10
0
Serum
glucose
Fig. 3. Effect of normal human serum in normal or elevated glucose
concentration on the prol(feration of mouse mesangial cells. Each
value represents mean SEM of four experiments in which transformed
cells were pulsed for 8 hours with [3H]-thymidine after culture for
48 hours in the presence of 5.5 m or 25 m glucose supplemented
with the concentrations indicated of dialyzed human serum (HS).
a P < 0.05 compared with 0% serum at same concentration of glucose;
b P < 0.05 compared with 3% serum at same concentration of
glucose; C P < 0.05 compared with same concentration of HS.
reported this finding, as well as the observations that incubation
in 25 m glucose for longer (72 hours) periods in serum-free
media inhibits proliferation compared with 5.5 m glucose, and
that the high glucose effects are not reproduced by supplemen-
tation with mannitol [11]. Absence of mannitol effect (19.5 mas
in 5.5 m glucose) on cell proliferation was confirmed again in
the present study. In contrast to the stimulated incorporation
with normal serum in normal glucose concentration, the addi-
tion of 3 to 10% normal human serum to media containing 25
m glucose resulted in a dose-dependent inhibition of thymi-
dine incorporation, with 46% and 68% inhibition at 3% and 10%
serum supplementation, respectively (Fig. 3).
These findings suggested that glycation of serum proteins
—
during the 48 hour exposure to high glucose concentration
might be responsible for the observed inhibition. Therefore, the
effect of glycated serum on mesangial cell proliferation was
directly examined, using two experimental approaches. First, in
analogy with the procedure described by Crowely et a! [7], cells
were grown in plastic microtiter wells that had been precoated
with normal serum or with four-day glycated serum by incubat-
ing the wells with 100 jsl of the corresponding serum solution for
three days at 4°C under sterile conditions. After aspiration of
the serum and washing with PBS, incorporation by cells grown
for 48 hours in serum-free media in the precoated wells was
compared with that by cells grown in untreated wells. Precoat-
ing with normal serum resulted in modest but significant stim-
ulation of thymidine incorporation, whereas precoating with
glycated serum significantly inhibited proliferation (Fig. 4). The
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Table 2. Effect of glycated serum in normal or elevated glucose
concentration on proliferation of mouse mesangial cells in culture
ii
125
100
75
50
25
0
Glucose Supplement cpm x 102/well
5.5mM 3%HS
10% HS
3% OS
10% GS
120±2
150 2.5
100 4.8a
57 10b
25mM 3%HS
lO%HS
3%GS
10% GS
202±9
122±8
200±883 a,b
0 HP 4D-GP 0 HP 4D-GP
Coating
Each value represents mean SEM of four experiments in which cells
were pulsed for 8 hours with [3H]-thymidine after culture for 48 hours
in the presence of 5.5 m or 25 m glucose supplemented with the
concentrations indicated of dialyzed normal human serum (HS) or
serum that had been incubated for four days with 28 m glucose before
dialysis (OS).
a p < 0.05 compared with same concentration of HS
b P < 0.05 compared with 3% OS
15
10
ci)C
E
>., 5
0
Antibody
supplement
0 5 20 0 5 20 0 5 20
10%HS 10%GS 10%GS
Fig. 4. Effect of precoating of microtiter wells on mouse mesangial cell
proliferation. Each value represent mean SEM of 6 experiments in
which transformed cells were pulsed for 8 hours with [3H]-thymidine
after culture for 48 hours in serum-free media containing 5.5 m or 25
m glucose in plastic microtiter wells that were untreated or had been
precoated with normal serum (HP) or with 4-day glycated serum
(4D-HP). < 0.05 compared with untreated microtiter wells; #D <
0.05 compared with microtiter wells precoated with normal serum.
inhibitory effect in cells cultured in normal (5.5 mM) glucose
was modest (13% inhibition), but was striking in cells cultured
in 28 m glucose (34% inhibition). Second, incorporation by
cells grown in untreated wells and incubated with media sup-
plemented with glycated serum was compared with incorpora-
tion by cells incubated with media supplemented with normal
serum. Serum glycated in vitro for four days dramatically
inhibited proliferation in media containing 5.5 m glucose
(Table 2); this effect was dose-dependent on the concentration glucose 5.5 mM 5.5 mM 25 mM
of glycated serum (17% inhibition and 62% inhibition at 3% and Fig. 5. Effectof A717 monoclonal antibody on glycation-induced inhi-
10% glycated serum, respectively). Glycated serum in 25 mM bition of mesangial cell pro1feration. Each value represents mean
glucose media exaggerated the high-glucose induced inhibition
of mesangial cell growth. Relative to 10% normal serum in 5.5
.m glucose, 10% normal serum in 25 m glucose inhibited
incorporation by 19%; relative to 10% normal serum in high
SEM of four experiments in which transformed cells were pulsed for 8
hours with E3H]-thymidine after culture for 48 hours in the indicated
glucose concentration supplemented with unincubated human serum
(HS) or serum glycated by incubation for 4 days with 28 m glucose
(OS), without (0) or with A7l7 monoclonal antibody. < 0.05
glucose, 10% glycated serum inhibited incorporation by 33% compared with no antibody added.
(Table 2). These changes in thymidine incorporation were
accompanied by parallel changes in cell counts. In cells grown
in 5.5 m glucose for 48 hours, cell counts were reduced 8.8% glucose, and did not influence incorporation stimulated by
in 3% glycated serum relative to 3% normal serum. In cells normal serum in normal or elevated glucose. However, A7l7
grown in 25 m glucose, the reduction in cell number by restored proliferative activity in cells incubated with glycated
glycated serum was 19.5% (N = 4 for each condition), Because serum and normal or elevated glucose concentration (Fig. 5).
culture in media containing glycated proteins in soluble phase The A7l7 effect showed a dose response relationship in cultures
more likely resembles the in vivo situation, where the me- incubated with 25 mivi glucose. The observed effects were
sangium is bathed by serum presented by the circulation, specific for the A7l7 antibody since the addition of 5 to 20 gJml
further experiments were conducted in media supplemented of mouse or rabbit IgG that do not react with glycated albumin
with glycated serum in the soluble phase. had no effect. Notably, the addition of A717 antibody to cells
Addition of A717 monoclonal antibody to mesangial cell cultured with glycated serum restored thymidine incorporation
cultures had no effect on basal incorporation in 5.5 or 25 m to levels approximating those observed with cells cultured with
•
 I. •
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m
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100 450
Fig. 6. Representative autoradiograph of a
Northern blot showing effect of culture
medium composition on mRNA levels of the
alpha 1 chain of Type IV collagen and
GAPDH in non-transformed murine
glomerular mesangial cells. Cells were
cultured for 72 hours in DMEM containing
100 (A, 5.5 mM) or 450 (B, 25 mM) mg/dl
glucose. Lanes 1 and 5 (C), serum-free contro
media; lanes 2 and 6 (F), 3% fetal calf serum;
lanes 3 and 7 (N), 3% normal (unincubated)
human serum; and lanes 4 and 8 (G), 5-day
glycated human serum. The same filter was
stripped and re-probed with GAPDH to
control for equivalent RNA loading and
transfer. Similar results were obtained in two
separate experiments.
normal serum, and did not stimulate incorporation to levels
greater than those observed in normal serum-supplemented
cultures. Further, addition of A717 antibody to cells cultured
with normal serum did not stimulate incorporation to levels
greater than those observed without antibody. These findings
militate against a non-specific antibody-mediated effect on
proliferation through occupancy and activation of mesangial Fc
receptors by antibody or by glycated albumin immune com-
plexes. Response to A717 also was demonstrable with cell
counts. In cells grown with 5.5 m glucose plus 3% glycated
serum, the addition of 5 p,g/ml A7l7 monoclonal antibody
increased cell counts by 17% compared with cell number in
cultures grown under the same conditions but supplemented
with 5 sg/ml mouse IgG that was not reactive with glycated
albumin.
To determine if increased matrix synthesis accompanied the
glycation-induced decrease in proliferation, which together are
hallmarks of mesangial cell biology in diabetes, we examined
Type IV collagen gene expression and secretion. Northern blot
analysis using a cDNA probe for alpha1-Type IV collagen
demonstrated constitutive expression of the niRNA for collagen
Type IV by non-transformed munne mesangial cells in serum
free media containing 5.5 or 25 m glucose, although Type IV
collagen mRNA expression was stimulated in the high glucose
concentration medium (Fig. 6). Supplementation with FCS or
normal human serum had only a modest effect on Type IV
collagen mRNA expression in either normal or elevated glucose
concentration, but higher levels of expression were observed in
FCS or NS-supplemented cells grown in high glucose concen-
tration (Fig. 6). Cells grown in media supplemented with 3%
glycated human serum expressed levels of Type IV collagen
mRNA that were appreciably increased compared with those in
cells grown in media supplemented with normal human serum.
This effect was observed in both 5.5 and 25 m glucose
concentration, but was much more dramatic in high glucose
concentration (Fig. 6). Densitometric scanning of the exposed
films allowed calculation of relative RNA levels to adjust for
small variations in RNA loading and transfer. Table 3 presents
Type IV collagen to GAPDH ratios in RNA isolated from cells
grown under the various culture conditions. Relative to serum-
Glucose concentration Supplement
Type IV:
GAPDH
5.5mM none
FCS
NS
GS
1.00
1,20
1.45
1.60
25 m none
FCS
NS
GS
2.35
2.80
2.90
9.00
Serum supplements at 3%. Data obtained by densitometric scanninl
of autoradiographs of Type IV collagen and GAPDH hybridizatiot
assay, and represent the mean of two separate experiments under eacl
condition. Abbreviations are: FCS, fetal calf serum; NS, normal humai
serum; GS, glycated human serum. Values represent ratios compare
with no serum supplement in 5.5 m glucose, assigned an arbitrar
value of 1.00.
free media in 5.5 m media glucose concentration, normal an
glycated human serum in 5.5 m media glucose resulted in 459i
and 60% increases in collagen mRNA, respectively; in 25 mt
glucose concentration, normal serum increased collagen mRN
about threefold whereas glycated serum induced a ninefok
increase. Relative to serum-free media in 25 mM glucose
concentration, normal serum increased collagen mRNA 23%
whereas glycated serum induced an almost fourfold increase.
The changes in Type IV collagen mRNA expression accom
panying exposure of mesangial cells to nonenzymatically gly
cated serum proteins were associated with parallel increases ii
Type IV collagen secreted into the media, which we and othen
have shown accounts for approximately 80% of the Type I\
collagen produced by mesangial cells cultured in the presence
of j3-aminopropionitrile [6, 291. Cells cultured during the exper
imental period in the absence of serum secreted detectable bu
very low levels of Type IV collagen into the medium. Supple
mentation with normal human serum resulted in a twofok
increase in collagen secretion compared with non-supple
mented media in normal or elevated glucose concentration
Supplementation with glycated serum significantly stimulate
6.5 kb — ]— al (IV)
1.3kb —
— GAPDH
1 2 3 4 56 78
Table 3. Type IV collagen/GAPDH mRNA ratios
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Type IV collagen secretion, and this effect was exaggerated in
high glucose concentration (Fig. 7). Relative to normal serum,
glycated serum induced a 33% increase in 5.5 m glucose
concentration, and an 80% increase in 25 m glucose concen-
tration. This marked stimulation of Type IV collagen produc-
tion by glycated serum in normal or elevated glucose concen-
tration greatly exceeded the modest effect on total protein
synthesis, measured by 3H-leucine incorporation, under similar
conditions. In cells grown in 5.5 m glucose for 48 hours, 3%
glycated serum increased tritiated leucine incorporation only
10% compared with incorporation in the presence of 3% normal
serum (194 18 vs. 176 17 cpmIlO3 cells, respectively; N =
4each condition; P = NS). In cells grown in 25 m glucose, the
increase was 16% (from 272 21 to 316 18 cpm/103 cells;N = 4 each condition; P < 0.05). Supplementation with
mannitol (19.5 m in 5.5 m glucose) was without effect on
collagen IV production or leucine incorporation [11].
Addition of A717 antibody had no effect on collagen secretion
by cells cultured in the presence of normal human serum, but
prevented the increased secretion associated with culture in the
presence of glycated human serum (Fig. 7). The prevention of
glycated serum-induced increase in collagen production was
specific for the A717 antibody, since the addition of mouse
or rabbit IgG not containing antibodies to glycated albumin
had no effect. A717 or other IgG added to cells cultured in
the absence of serum, whether in low or high glucose con-
centration, also had no effect. Notably, addition of A717 to
cells cultured with glycated serum restored collagen secretion
to levels observed with cells cultured with normal serum, and
did not inhibit production to levels lower than those observed
in normal serum-supplemented cultures. Further, addition
of A717 antibody to cells cultured with normal serum did
not depress collagen synthesis to levels lower than those
observed without antibody or to levels observed in cells grown
in the absence of serum. As discussed above, these findings
indicate that the reversal of the stimulatory effect of glycated
serum was due to blocking of glycated epitopes in albumin and
not a non-specific Fc-mediated signal inhibiting collagen syn-
thesis.
Discussion
Previous studies have examined the effect of glucose per se
on proliferation of mesangial cells, reporting variable results
including stimulation, no effect, or inhibition, depending on cell
type, duration of exposure to glucose, or culture conditions [11,
29, 36—39]. An effect of nonenzymatic glycation of serum
proteins and of Amadori adducts in a particular serum protein
on cell proliferation has not been demonstrated previously.
Crowley et al found that plating rat mesangial cells onto
extracellular matrix that had been elaborated by the cells in
culture and was modified by incubation with glycoaldehyde (50
mM) or G-6-P (200 mM) reduced [3H}-thymidine incorporation
relative to incorporation by cells plated onto unmodified matrix
[7]. However, the elaborated matrix contained laminin, fi-
bronectin and collagen but no albumin; glycoaldehyde is a
highly cross-linking glycation product; and both G-6-P and
glycoaldehyde modified matrices were highly fluorescent, indi-
cating extensive formation of AGE products. The inhibition of
cell proliferation in that study was therefore ascribed to glyca-
tion-induced cross-linking of matrix components, which was
0
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Fig. 7. Type IV collagen secretion by non-transformed mouse mesan-
gial cells cultured in media containing 5.5 m (A) or 25 mw (B) glucose
in the presence of 3% normal (NS) or glycated (GS) human serum,
without (open bars) or with the addition of IgG not reactive with
glycated albumin (hatched bars) or A717 monoclonal antibody (lined
bars). Results represent mean SEM of four separate experiments
under each culture condition. p < 0.05 compared with NS without IgG
or A717 added.
consistent with the investigators' finding that inhibition ap-
peared proportional to the degree of cross linking assessed by
fluorophore analysis.
The present results, in contrast, demonstrate that glycated
serum proteins without cross-links or AGE fluorescence inhibit
cell growth and stimulate Type IV collagen production, and that
these effects are due to Amadori adducts. Four considerations
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support this interpretation. First, incubation of serum was kept
to four to five days and performed under conditions known to
yield Amadori and not AGE modification [25, 26, 35]. Second,
the A717 antibody was raised against glycated albumin that was
purified from normal plasma, representing albumin glycated in
vivo, and did not contain AGE-modified albumin. Third, the
antibody specifically immunoreacts with glycated lysine
epitopes in albumin, does not recognize nonglycated albumin
and does not immunoreact with protein in the phenylboronate
(PBA) pass-through after application of albumin prepared from
human plasma or of albumin glycated in vitro. Even if AGE
products of serum glycoalbumin are formed in vivo or in vitro
after four to five days of incubation, they would be present in
the PBA pass-through since co-planar cis-hydroxyl groups are
required for binding to PBA. AGE products, which are irre-
versibly formed, do not have this configuration. The ability of
the A717 antibody to react with unreduced or borohydride-
reduced glycoalbumin is consistent with recognition of a fruc-
tosyl adduct, with equilibrium shifted to linear configuration by
borohydride reduction. Further, the antibody does not immu-
noreact with other proteins, whether glycated or not, strongly
suggesting that glycated albumin is responsible for the observed
effects. This contrasts with antibodies raised against AGE
products, reported to prevent cell biology effects of AGE-
modified proteins, which recognize immunologic epitopes that
appear to be common to many different proteins after incuba-
tion for prolonged periods with high concentrations of reducing
sugars [20].
Glycated serum containing increased concentrations of gly-
cated albumin stimulated collagen production relative to normal
serum containing normal concentrations of glycated albumin.
An effect of A717 antibody was only observed in cells cultured
with glycated serum; the antibody had no effect on collagen
synthesis by cells cultured with fetal calf or normal serum.
Abrogation of the glycated serum effect by A717 antibody
indicates that (increased) glycated albumin is responsible for
the increased collagen synthesis relative to normal serum. If
occupancy of the Fc receptor by glycated albumin immune
complexes caused (non-specific) inhibition of collagen synthe-
sis, such an effect would have been observed in cells cultured in
normal serum in the presence of antibody.
The results presented in these experiments are the first to
demonstrate that Amadori adducts in nonenzymatically gly-
cated serum proteins induce increases in mesangial cell collagen
Type IV gene expression. In these experiments, we used
mesangial cells cultured in media containing glycated serum,
which resembles the in vivo situation where the mesangium is
bathed in serum presented by the circulation. We believe that
culture in media containing glycated proteins in soluble phase,
in amounts representative of those found in diabetic serum and
in Amadori configuration, more likely represents the in vivo
milieu than does culture of cells in plates onto which proteins
extensively modified by advanced glycation end (AGE) prod-
ucts have been immobilized or in medium to which AGE-
modified bovine albumin in excessive amounts is added [7, 8].
Supplementation of culture media with normal or glycated
serum also is more representative of in vivo physiology than is
culture in serum-free media, and the observed stimulation of
collagen gene expression by glycated serum proteins adds to
our understanding of hyperglycemia-related pathophysiologic
changes in mesangial cells. Further, we suggest that the stimu-
lation of Type IV collagen gene expression and production by
glycated serum that was observed with physiologic glucose
concentration and was accentuated with high glucose concen-
tration approximates the in vivo situation in which there are
periods of normoglycemia and hyperglycemia. It is interesting
to note that the glycation-induced changes in proliferation,
collagen secretion, and collagen gene expression were observed
in normal glucose concentration and were accentuated in ele-
vated glucose concentration. Sabbatini et al also found that
acute hyperglycemia caused an impressive exaggeration of
the glycated serum-induced hyperifitration in non-diabetic rats
[25].
We recognize that caution should be exercised in extrapolat-
ing data from tissue culture studies to the in vivo state.
Nevertheless, we believe that these results, taken in context
with other studies, are highly relevant to the pathogenesis of
diabetic nephropathy. Glycated albumin, which is increased in
diabetic serum, is known to enter the renal glomerulus in vivo,
where it is taken up more avidly than nonglycated albumin [15,
18, 21—24]. Nondiabetic mice injected with glycated plasma
proteins have developed glomerular basement membrane thick-
ening, endogenous albumin binds to the glomerular basement
membrane, and there is widespread connective tissue accumu-
lation of glycated protein in diabetes [40—43]. Enhanced uptake
of glycated albumin by glomerular mesangial and epithelial cells
is accompanied by adverse metabolic changes [24]. The gly-
cated protein-induced inhibition of cell proliferation and stimu-
lation of collagen production parallel effects that have been
observed with certain important growth factors such as TGF-3,
which has been shown to be anti-mitogenic and pro-sclerotic in
a variety of cells, including mesangial cells [11, 44]. Increased
elaboration of matrix macromolecules by mesangial cells is
considered to be an early and characteristic lesion in diabetic
nephropathy; decreased cellularity as mesangial matrix accu-
mulates and diversion of growth potential to synthesis of matrix
macromolecules, as shown in these experiments, is consistent
with pathologic findings.
The mechanisms by which glycated serum proteins lead to
inhibition of proliferation and stimulation of collagen gene
expression and collagen production are currently unknown, but
the findings suggest that there might be cell binding proteins
that specifically interact with Amadori adducts. This possibility
also was suggested by the studies of Predescu et al, which
demonstrated that glycated albumin can bind to endothelial
cells as a bifunctional ligand, with a plasma membrane site that
binds as a lectin glucose in glycated albumin and a plasmalem-
nial site that recognizes domains in the albumin molecule [451.
It is further supported by our recent identification in aortic
endothelial cells of glycated albumin-binding polypeptides [46].
Thus, it is possible that binding of this circulating glycated
protein to a plasma membrane site triggers receptor-induced
events, analogous to the many other models of ligand-receptor
interaction. Alternatively, glycated albumin may, after internal-
ization [45], be responsible for the observed consequences on
mesangial cell biology.
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